局部注射Janus-Kinase抑制剂Tofacitinib和Oclacitinib显示令人印象深刻的止痒剂和抗炎反应过敏性皮炎的典范。
文章的细节
-
引用
复制到剪贴板 -
福山T,艾莉年代,库克E,鲍默W
局部注射Janus-Kinase抑制剂Tofacitinib和Oclacitinib显示令人印象深刻的止痒剂和抗炎反应过敏性皮炎的典范。
J Exp其他杂志》2015年9月,354 (3):394 - 405。doi: 10.1124 / jpet.115.223784。Epub 2015 7月9。
- PubMed ID
-
26159873 (在PubMed]
- 文摘
-
过敏性皮肤病的发病率迅速增长,发展仍需要治疗药物缓解症状。在这项研究中,我们口服或局部注射Janus激酶(激酶)抑制剂,tofacitinib oclacitinib,皮炎的小鼠模型,比较了疗效减少瘙痒和炎症反应。体外激酶抑制剂对骨的影响骨髓来源树突状细胞(BMDCs)进行了分析。过敏性皮炎模型,雌性BALB / c小鼠致敏和挑战toluene-2 4-diisocyanate (TDI)。每个木菠萝抑制剂口服或局部应用30分钟前和后4小时TDI的挑战。抓挠后发作和耳朵厚度测量、细胞因子测定在皮肤和细胞在淋巴结的挑战进行了分析通过流式细胞术。在体外,木菠萝抑制剂显著地抑制细胞因子的生产,迁移,BMDCs和成熟。小鼠口服木菠萝抑制剂明显下降抓挠行为;然而,耳朵厚度没有显著降低。相比之下,抓挠行为和耳朵的厚度局部治疗组与车辆治疗组相比显著降低。 However, cytokine production was differentially regulated by the JAK inhibitors, with some cytokines being significantly decreased and some being significantly increased. In conclusion, oral treatment with JAK inhibitors reduced itch behavior dramatically but had only little effect on the inflammatory response, whereas topical treatment improved both itch and inflammatory response. Although the JAK-inhibitory profile differs between both JAK inhibitors in vitro as well as in vivo, the effects have been comparable.
beplay体育安全吗DrugBank数据引用了这篇文章
- 药物